WCG acquires VeraSci to boost clinical trial offerings for CNS disorders
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

WCG acquires VeraSci to boost clinical trial offerings for CNS disorders

27 Jul 2021 (Last Updated July 27th, 2021 15:33)

VeraSci will extend WCG’s capabilities to address the challenges related to the planning and implementation of CNS trials.

WCG acquires VeraSci to boost clinical trial offerings for CNS disorders
The acquisition will further WCG’s services for trials in central nervous system therapeutic areas. Credit: fernando zhiminaicela / Pixabay.

WCG has acquired VeraSci, which offers capabilities and eClinical software to design and perform clinical trials for central nervous system (CNS) disorders, to boost its trial technology and services.

Financial details were not disclosed.

VeraSci will support WCG’s scientific and patient engagement expertise, as well as CNS offerings, including those provided through its MedAvante, ProPhase and Analgesic Solutions units.

WCG expects the deal to help meet the rising demand for scientific and technological solutions that can enable the remote collection of data, hybrid virtual trials and entirely decentralised trials in main CNS therapy indications.

In addition, VeraSci will enhance WCG’s capabilities to address the challenges related to CNS trial planning and implementation.

VeraSci has experience across all development phases, from single-centre, Phase I trials to international Phase III trials.

WCG executive chairman and CEO Donald Deieso said: “On behalf of WCG, I’m proud to welcome VeraSci, an organisation that shares our dedication to improving the clinical trial experience for patients and sites, commitment to scientific rigour and passion for bringing novel technologies into clinical trial processes.”

VeraSci portfolio consists of solutions to enhance data quality in trials, which include endpoint and assessment services, rater training and certification, language and translation support, along with eCOA and ePRO technologies.

The company’s Pathway technology platform is designed for easy adoption to any study worldwide.

VeraSci uses Pathway to capture data that enables the evaluation of symptoms, cognition and functional capacity in a variety of therapeutic areas.

VeraSci CEO and co-founder Rich Keefe said: “Since our inception, we have invested in expanding VeraSci’s expertise and capabilities to include a variety of clinical and regulatory endpoints covering a range of diseases and disorders.

“We have also pioneered technological advances that are changing the way subjective endpoint assessments are conducted in clinical research.”

The company will leverage the acquisition to scale up and bolster its offerings.

VeraSci will operate as WCG VeraSci and continue its leadership structure. It will also retain its headquarters in North Carolina, US.

In May, WCG acquired The Avoca Group to expand its portfolio of solutions for enhancing clinical trial quality management and compliance transformation.